Alnylam Partners with Viz.ai and American Heart Association to Improve ATTR-CM Care

Alnylam Pharmaceuticals has entered new collaborations with Viz.ai and the American Heart Association to improve care for patients with ATTR-CM. The partnerships focus on AI-enabled screening, earlier recognition, and coordinated care pathways across health systems. These initiatives aim to address long-standing gaps in diagnosis and management of a rare cardiomyopathy that often goes undetected. The financial impact is not yet clear, but the collaborations relate directly to how treatments reach patients in real clinical settings.